HELIOS Kliniken

Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma (2022) Straka C, Schaefer-Eckart K, Hertenstein B, Bassermann F, Salwender H, Langer C, Kroenke J, et al. Conference contribution In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial (2022) Stelljes M, Middeke JM, Bug G, Wagner EM, Mueller LP, Christoph S, Krause S, et al. Conference contribution CFR-PEEK Pedicle Screw Instrumentation for Spinal Neoplasms: A Single Center Experience on Safety and Efficacy (2022) Joerger AK, Seitz S, Lange N, Aftahy AK, Wagner A, Ryang YM, Bernhardt D, et al. Journal article Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT) (2022) Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, et al. Conference contribution GeparPiPPa- A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC) (2022) Loibl S, Reinisch M, Denkert C, Schneeweiss A, Seiler S, Fasching P, Hanusch C, et al. Conference contribution Meeting Medical Need - Development of a High-Throughput Assay Using Pancreatic Cancer Patient Derived Organoids as a Tool for Personalized Medicine (2022) Sankarasubramanian S, Niethard M, Pilarsky C, Regenbrecht C, Wedeken L Conference contribution Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522 (2022) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kuemmel S, Bergh J, et al. Conference contribution Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response (2022) Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU, Furlanetto J, et al. Journal article Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS) (2022) Bielack SS, Blattmann C, Borkhardt A, Csóka M, Hassenpflug W, Kabíčková E, Kager L, et al. Journal article Higher risk of short term COVID-19 vaccine adverse events in myositis patients with autoimmune comorbidities: results from the COVAD study (2022) Dey M, Naveen R, Nikiphorou E, Sen P, Saha S, Lilleker JB, Agarwal V, et al. Journal article, Letter